Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia

NCT00456976 is registered in ClinicalTrials.gov with Tabriz University as lead sponsor.

NCT NCT00456976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00456976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia
Lead sponsor
Tabriz University
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2007
Completion date
September 30, 2007
Enrollment
70
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia